跳至主要内容
临床试验/NCT01880619
NCT01880619已完成4 期

A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms

Mansoura University1 个研究点 分布在 1 个国家目标入组 131 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
131
试验地点
1
主要终点
The Efficacy of tamsulosin and solifenacin in relieving ureteral stent symptoms will be evaluated by comparing the scores of ureteral stent symptoms questionnaire in the studied groups

研究概览

简要总结

This study will be conducted to compare the effectiveness of alpha blocker (Tamsulosin) and Anticholinergic (Solifenacin) in relieving lower urinary tract symptoms caused DJ ureteral stents.

详细描述

Eligible patients who signed the informed consent will randomly assigned to one of 3 groups; group 1 (control), group 2 (tamsulosin) and group 3 (Solifenacin). Ureteral stent symptom questionnaire (USSQ) will be used to compare health related quality of life scores.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who will undergo unilateral ureteral stent fixation:
  • To relieve upper urinary tract obstruction caused by ureteric calculi
  • After ureteroscopic lithotripsy for ureteral calculi.

排除标准

  • Patients who had LUTS before stent fixation.
  • Ureteral stent fixation after open or laparoscopic surgery.
  • Bilateral ureteral stents.
  • Patients who developed complications related to the primary endoscopic procedure
  • Patients who developed stent related complications such as hematuria, acute pyelonephritis or stent displacement

研究组 & 干预措施

Group A

Placebo Comparator

Patients in this group will receive placebo

干预措施: Control (Drug)

Group B

Active Comparator

Patients in this group will receive Tamsulosin

干预措施: Tamsulosin (Drug)

Group C

Active Comparator

Patients in this group will receive Solifenacin

干预措施: Solifenacin (Drug)

结局指标

主要结局

The Efficacy of tamsulosin and solifenacin in relieving ureteral stent symptoms will be evaluated by comparing the scores of ureteral stent symptoms questionnaire in the studied groups

时间窗: 1 year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed R. EL-Nahas

Assistant Professor

Mansoura University

研究点 (1)

Loading locations...

相似试验